Global Acute Renal Failure Market is segmented By Disease Type (Prerenal Acute Renal Failure, Renal Acute Renal Failure, Postrenal Acute Renal Failure), By Drug Type (Diuretics, Vasopressors, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Calcium and Vitamin D Supplements, Antibiotics, Others), By Route of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The Global Acute Renal Failure Market reached US$ 5.30 million in 2023 and is expected to reach US$ 11.02 million by 2031, growing at a CAGR of 9.0% during the forecast period 2024-2031.
Acute renal failure (ARF), also known as acute kidney injury (AKI), is a sudden decline in kidney function caused by factors like severe dehydration, infections, certain medications, or underlying medical conditions like diabetes or hypertension. It results in the kidneys' inability to filter waste products and excess fluids, leading to the accumulation of toxic substances in the body. ARF is characterized by decreased urine output, fluid retention, electrolyte imbalances, and potentially life-threatening complications. Prompt diagnosis and treatment are crucial for managing ARF and preventing its progression to chronic kidney disease.
Market Scope
| Metrics | Details |
| CAGR | 9.0% |
| Market Size Available for Years | 2022-2031 |
| Estimation Forecast Period | 2024-2031 |
| Revenue Units | (US$ Mn) |
| Segments Covered | Disease Type, Drug Type, Route of Administration, Distribution Channel, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Rise in the prevalence of kidney diseases
The increasing prevalence of acute renal failure (ARF) is influencing the treatment market, driven by factors like chronic diseases, aging populations, and improved diagnostic capabilities. This leads to a surge in demand for effective treatment options.
For instance, according to an article published in NCBI, acute renal failure is commonly seen in hospitalized patients. In the United States, 1% of all hospital admissions have AKI on admission. During hospitalization, the approximate incidence rate of acute kidney injury is 2% to 5%, and it occurs in up to 67% of patients admitted to the intensive care unit. AKI is thus an important contributor to more extended hospital stays and patient morbidity.
Side effects associated with the drugs
Acute renal failure treatment often involves various drugs, including diuretics, vasopressors, erythropoiesis-stimulating agents (ESAs), phosphate binders, antibiotics, and antibiotics. These drugs can cause side effects like dehydration, electrolyte imbalances, hypotension, arrhythmias, tissue ischemia, severe hypertension, thromboembolic events, hypertension, gastrointestinal issues, and antibiotic resistance.
It is crucial to manage these side effects carefully to avoid exacerbating renal dysfunction or causing additional health problems. It is essential to monitor these medications closely to ensure proper treatment and recovery.
Market Segment Analysis
The global acute renal failure market is segmented based on disease type, drug type, route of administration, distribution channel, and region.
The diuretics from the drug type segment accounted for approximately 41.1% of the acute renal failure market share
The diuretics from the drug type segment accounted for approximately 41.1%. Diuretics are essential in acute renal failure to manage fluid overload and electrolyte imbalances. They increase urine production, reducing fluid volume and preventing complications like pulmonary edema and hypertension. They also manage electrolyte disturbances like hyperkalemia, often associated with the condition. However, the use of diuretics must be monitored to avoid potential side effects like dehydration and electrolyte imbalances, which can further stress the renal system.
For instance, in December 2023, A new Vanderbilt University Medical Center genetic association study of more than 1 million adults supported the use of thiazide diuretics for kidney stone prevention. Kidney stones affect nearly 10% of the global population. For more than three decades, thiazide diuretics, a common medication used for high blood pressure, have been the standard of care for kidney stone prevention because they reduce the excretion of urinary calcium.
Market Geographical Share
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like novel product launches, FDA approvals, a rise in cases of acute renal failure, and other factors that help the region to grow during the forecast period.
For instance, in January 2023, the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD).
Market Segmentation Analysis
By Disease Type
- Prerenal Acute Renal Failure
- Renal Acute Renal Failure
- Postrenal Acute Renal Failure
By Drug Type
- Diuretics
- Vasopressors
- Erythropoiesis-Stimulating Agents (ESAs)
- Phosphate Binders
- Calcium and Vitamin D Supplements
- Antibiotics
- Others
By Route of Administration
- Oral
- Intravenous
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Market Companies
The major global players in the market include Novartis, Fresenius Medical Care, Amgen, Roche, Baxter International Inc, Zypharma, Nature Made, Pfizer, GSK, and Eli Lilly among others.
Why Purchase the Report?
- To visualize the global acute renal failure market segmentation based on disease type, drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of the acute renal failure market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global acute renal failure market report would provide approximately 64 tables, 61 figures, and 186 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
